Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Linezolid, an oxazolidinone antibiotic, is recommended for vancomycinresistant enterococci (VRE). However, 100% free-drug concentration above the minimum inhibitory concentration (fT>MIC) and an area under the curve of free drug to MIC ratio (fAUC24/MIC) >100 were associated with favorable clinical outcome with less emerging resistance. A plasma trough concentration (Ctrough) of linezolid ≥9 µg/mL was also related to hematologic toxicity. Thus, linezolid dose optimization is needed for VRE treatment. The study aimed to determine the in vitro linezolid activity against clinical VRE isolates and linezolid dosing regimens in critically ill patients who met the target pharmacokinetics/ pharmacodynamics (PK/PD) for VRE treatment. Materials and Methods: Enterococcal isolates from enterococcal-infected patients were obtained between 2014 and 2018 at Phramongkutklao Hospital. We used Monte Carlo simulation to calculate the probability of target attainment, and the cumulative fraction of response (CFR) of the free area under the curve to MIC ratio (fAUIC24) was used to calculate the fAUC24/MIC 80 - 100 and fT/MIC >85 - 100% of the interval time of administration for clinical response and microbiological eradication as well as the Ctrough ≥9 µg/mL for the probability of hematologic toxicity. Results: For linezolid MIC determination, the MIC median (MIC50), MIC for 90% growth (MIC90), and range for linezolid were 1.5 µg/mL, 2 µg/mL, and 0.72 - 2 µg/mL, respectively. A dosing regimen of 1,200 mg either once daily or as a divided dose every 12 h gave target attainments of fAUC24/MICs >80 and >100, which exceeded 90% for MICs ≤1 and ≤1 µg/mL, respectively, with a rate of hematologic toxicity <15%. If the expected fT>MICs were >85% and 100%, a 1,200-mg divided dose every 12 h could cover VRE isolates having linezolid MICs ≤1 µg/mL and ≤0.75 µg/mL. Even 600 mg every 8 h and 1,200 mg as a continuous infusion gave a higher target attainment of fAUC24/MIC and a fT>MIC and the target CFR, but those regimens gave Ctrough ≥9 µg/mL rates of 40.7% and 99.6%. Conclusion: The current dosing of 1,200 mg/day might be optimal treatment for infection by VRE isolates with documented MICs ≤1 µg/mL. For treatment of VRE with a MIC of 2 µg/mL or to achieve the target CFR, the use of linezolid with other antibiotic combinations might help achieve the PK/PD target, provide better clinical outcome, and prevent resistance.
Abstract
Background: Linezolid, an oxazolidinone antibiotic, is recommended for vancomycinresistant enterococci (VRE). However, 100% free-drug concentration above the minimum inhibitory concentration (fT>MIC) and an area under the curve of free drug to MIC ratio (fAUC24/MIC) >100 were associated with favorable clinical outcome with less emerging resistance. A plasma trough concentration (Ctrough) of linezolid ≥9 µg/mL was also related to hematologic toxicity. Thus, linezolid dose optimization is needed for VRE treatment. The study aimed to determine the in vitro linezolid activity against clinical VRE isolates and linezolid dosing regimens in critically ill patients who met the target pharmacokinetics/ pharmacodynamics (PK/PD) for VRE treatment. Materials and Methods: Enterococcal isolates from enterococcal-infected patients were obtained between 2014 and 2018 at Phramongkutklao Hospital. We used Monte Carlo simulation to calculate the probability of target attainment, and the cumulative fraction of response (CFR) of the free area under the curve to MIC ratio (fAUIC24) was used to calculate the fAUC24/MIC 80 - 100 and fT/MIC >85 - 100% of the interval time of administration for clinical response and microbiological eradication as well as the Ctrough ≥9 µg/mL for the probability of hematologic toxicity. Results: For linezolid MIC determination, the MIC median (MIC50), MIC for 90% growth (MIC90), and range for linezolid were 1.5 µg/mL, 2 µg/mL, and 0.72 - 2 µg/mL, respectively. A dosing regimen of 1,200 mg either once daily or as a divided dose every 12 h gave target attainments of fAUC24/MICs >80 and >100, which exceeded 90% for MICs ≤1 and ≤1 µg/mL, respectively, with a rate of hematologic toxicity <15%. If the expected fT>MICs were >85% and 100%, a 1,200-mg divided dose every 12 h could cover VRE isolates having linezolid MICs ≤1 µg/mL and ≤0.75 µg/mL. Even 600 mg every 8 h and 1,200 mg as a continuous infusion gave a higher target attainment of fAUC24/MIC and a fT>MIC and the target CFR, but those regimens gave Ctrough ≥9 µg/mL rates of 40.7% and 99.6%. Conclusion: The current dosing of 1,200 mg/day might be optimal treatment for infection by VRE isolates with documented MICs ≤1 µg/mL. For treatment of VRE with a MIC of 2 µg/mL or to achieve the target CFR, the use of linezolid with other antibiotic combinations might help achieve the PK/PD target, provide better clinical outcome, and prevent resistance.
참고문헌 (34)
- Reyes K, "Vancomycin-resistant enterococci: epidemiology, infection prevention, and control", Infect Dis Clin North Am, 30, pp.953~965 (2016)
- Ahmed MO, "Vancomycin-resistant enterococci: a review of antimicrobial resistance mechanisms and perspectives of human and animal health", Microb Drug Resist, 24, pp.590~606 (2018)
- "WHO publishes list of bacteria for which new antibiotics are urgently needed"[URL]
- "Thailand" (2018)[URL]
- Rice LB, "Emergence of vancomycin-resistant enterococci", Emerg Infect Dis, 7, pp.183~187 (2001)
- O'Driscoll T, "Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management", Infect Drug Resist, 8, pp.217~230 (2015)
- Prematunge C, "VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis", Infect Control Hosp Epidemiol, 37, pp.26~35 (2016)
- Hemapanpairoa J, "Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect", Infect Drug Resist, 12, pp.2049~2057 (2019)
- Ager S, "Clinical update on linezolid in the treatment of Gram-positive bacterial infections", Infect Drug Resist, 5, pp.87~102 (2012)
- Mendes RE, "Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12)", J Antimicrob Chemother, 69, pp.1582~1588 (2014)
- Senior K, "FDA approves first drug in new class of antibiotics", Lancet, 355, pp.1523~ (2000)
- Dong H, ". Developments in the pharmacokinetic", pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients, 2014, pp.22, 35~40
- Theuretzbacher U, "Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer", Clin Infect Dis, 54, pp.1785~1792 (2012)
- Rayner CR, "Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme", Clin Pharmacokinet, 42, pp.1411~1423 (2003)
- Tsuji BT, "Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations", J Antimicrob Chemother, 67, pp.2182~2190 (2012)
- Cattaneo D, "Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections", Int J Antimicrob Agents, 41, pp.586~589 (2013)
- Pea F, "Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients", J Antimicrob Chemother, 67, pp.2034~2042 (2012)
- Wichai Santimaleeworagun, "Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections", Infection and Chemotherapy, 52(3), pp.345~351 (2020), 대한감염학회[DOI]
- "National Healthcare Safety Network (NHSN) patient safety component manual: Identifying Healthcare-associated Infections (HAI) for NHSN surveillance"[URL]
- Clinical and Laboratory Standards Institute (CLSI), "Performance standards for antimicrobial susceptibility testing: Twenty-ninth informational supplement", pp.282~ (2019), CLS
- Meagher AK, "Population pharmacokinetics of linezolid in patients treated in a compassionate-use program", Antimicrob Agents Chemother, 47, pp.548~553 (2003)
- Barrasa H, "Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic", pharmacodynamic perspective, 2020, pp.93, 329~338
- Falagas ME, "Benefit-risk assessment of linezolid for serious gram-positive bacterial infections", Drug Saf, 31, pp.753~768 (2008)
- Narayanan N, "Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia", Ther Adv Infect Dis, 6, pp.2049936119828964~ (2019)
- Chen KH, "In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia", Antimicrob Agents Chemothe, 59, pp.6262~6265 (2015)
- Houri H, "Linezolid activity against clinical Gram-positive cocci with advanced antimicrobial drug resistance in Iran", J Glob Antimicrob Resist, 10, pp.200~203 (2017)
- Bender JK, "Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature", Drug Resist Updat, 40, pp.25~39 (2018)
- Taubert M, "Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens", J Antimicrob Chemother, 72, pp.2304~2310 (2017)
- Adembri C, "Linezolid pharmacokinetic", pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion, 2008, pp.31, 122~129
- Kim HS, "Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study", J Clin Pharm Ther, 44, pp.84~90 (2019)
- Boak LM, "Pharmacokinetic", pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model, 2007, pp.51, 1287~1292
- Zhao M, "Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis", Int J Antimicrob Agents, 48, pp.231~238 (2016)
- Mercuro NJ, "Combatting resistant enterococcal infections: a pharmacotherapy review", Expert Opin Pharmacother, 19, pp.979~992 (2018)
- . Dai Y, "Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients", J Clin Pharm Ther, 46, pp.807~813 (2021)